Spruce Biosciences (SPRB) Competitors $0.10 +0.00 (+4.24%) As of 03:32 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SPRB vs. DRRX, LPCN, PMN, GELS, ASBP, ALLR, MTEX, ATHA, FLGC, and EDSAShould you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include DURECT (DRRX), Lipocine (LPCN), Promis Neurosciences (PMN), Gelteq (GELS), Aspire Biopharma (ASBP), Allarity Therapeutics (ALLR), Mannatech (MTEX), Athira Pharma (ATHA), Flora Growth (FLGC), and Edesa Biotech (EDSA). These companies are all part of the "pharmaceutical products" industry. Spruce Biosciences vs. Its Competitors DURECT Lipocine Promis Neurosciences Gelteq Aspire Biopharma Allarity Therapeutics Mannatech Athira Pharma Flora Growth Edesa Biotech Spruce Biosciences (NASDAQ:SPRB) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership. Is SPRB or DRRX more profitable? DURECT has a net margin of -91.54% compared to Spruce Biosciences' net margin of -555.23%. Spruce Biosciences' return on equity of -62.10% beat DURECT's return on equity.Company Net Margins Return on Equity Return on Assets Spruce Biosciences-555.23% -62.10% -47.49% DURECT -91.54%-267.36%-64.00% Which has stronger valuation and earnings, SPRB or DRRX? DURECT has lower revenue, but higher earnings than Spruce Biosciences. DURECT is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpruce Biosciences$4.91M0.87-$47.92M-$1.32-0.08DURECT$2.03M8.60-$8.32M-$0.15-3.75 Which has more volatility & risk, SPRB or DRRX? Spruce Biosciences has a beta of 2.4, meaning that its stock price is 140% more volatile than the S&P 500. Comparatively, DURECT has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Does the media prefer SPRB or DRRX? In the previous week, DURECT had 1 more articles in the media than Spruce Biosciences. MarketBeat recorded 1 mentions for DURECT and 0 mentions for Spruce Biosciences. DURECT's average media sentiment score of 1.87 beat Spruce Biosciences' score of 0.00 indicating that DURECT is being referred to more favorably in the news media. Company Overall Sentiment Spruce Biosciences Neutral DURECT Very Positive Do analysts prefer SPRB or DRRX? Spruce Biosciences currently has a consensus price target of $1.75, indicating a potential upside of 1,637.84%. Given Spruce Biosciences' higher probable upside, analysts clearly believe Spruce Biosciences is more favorable than DURECT.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00DURECT 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders believe in SPRB or DRRX? 91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 28.0% of DURECT shares are owned by institutional investors. 6.9% of Spruce Biosciences shares are owned by company insiders. Comparatively, 3.2% of DURECT shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummarySpruce Biosciences beats DURECT on 8 of the 14 factors compared between the two stocks. Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SPRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRB vs. The Competition Export to ExcelMetricSpruce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.25M$752.17M$5.57B$9.31BDividend YieldN/A4.84%4.23%4.03%P/E Ratio-0.111.4328.6119.73Price / Sales0.8725.51411.31174.27Price / CashN/A19.5636.0257.96Price / Book0.056.608.235.67Net Income-$47.92M-$4.53M$3.23B$257.79M7 Day PerformanceN/A1.40%-0.01%0.52%1 Month PerformanceN/A1.30%5.60%8.84%1 Year Performance-82.93%3.42%26.54%14.18% Spruce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRBSpruce Biosciences2.0419 of 5 stars$0.10+4.2%$1.75+1,637.8%-83.3%$4.25M$4.91M-0.1120DRRXDURECT1.2079 of 5 stars$0.56-10.5%N/A-60.7%$17.39M$1.86M-3.7380Positive NewsGap DownLPCNLipocine3.0093 of 5 stars$3.20-2.1%$9.00+181.3%-58.0%$17.12M$3.67M-3.1410Positive NewsPMNPromis Neurosciences3.0815 of 5 stars$0.52+33.2%$4.33+733.3%-79.3%$17.00MN/A-10.405News CoverageAnalyst ForecastAnalyst RevisionGap DownHigh Trading VolumeGELSGelteqN/A$1.76-2.8%N/AN/A$16.61M$100K0.00N/APositive NewsGap DownASBPAspire BiopharmaN/A$0.33+0.3%N/AN/A$16.39MN/A0.00N/AGap UpALLRAllarity Therapeutics0.5759 of 5 stars$1.05+4.0%N/A-83.1%$15.83MN/A0.0010News CoverageMTEXMannatech1.3704 of 5 stars$8.31-2.2%N/A+14.8%$15.80M$117.87M-83.14250Positive NewsGap DownATHAAthira Pharma3.4579 of 5 stars$0.40-7.5%$11.25+2,696.4%-88.2%$15.71MN/A-0.1940Positive NewsFLGCFlora Growth2.6145 of 5 stars$0.69+0.6%$4.00+480.6%-39.9%$15.55M$53.26M-0.70280Positive NewsEDSAEdesa Biotech2.2463 of 5 stars$2.20+5.3%$5.00+127.3%-48.5%$15.44MN/A-1.3820Positive News Related Companies and Tools Related Companies DURECT Competitors Lipocine Competitors Promis Neurosciences Competitors Gelteq Competitors Aspire Biopharma Competitors Allarity Therapeutics Competitors Mannatech Competitors Athira Pharma Competitors Flora Growth Competitors Edesa Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SPRB) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersRevolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial UnderwayTiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare!Interactive Offers | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
